Effects of Pitavastatin on Remnant-Like Lipoprotein Particle Cholesterol in Patients with Dyslipidemia: A Randomized Controlled Trial-Reference-Cited by-同舟云学术

Effects of Pitavastatin on Remnant-Like Lipoprotein Particle Cholesterol in Patients with Dyslipidemia: A Randomized Controlled Trial

Published:2012 Issue:6 Volume:43 Page:375-380
ISSN:0388-1601
Container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:Jpn. J. Clin. Pharmacol. Ther.

Author:

DOMORI Takemasa¹,SAKUMA Nagahiko¹,SAEKI Tomoaki¹,OKAYAMA Naotsuka²,HIBINO Takeshi¹,NAGATA Takahiro¹,JOH Takashi²,SUZUKI Sadao³,YOSHIKAWA Masae⁴,SATO Toru⁵,KIMURA Genjiro¹

Affiliation:

1. Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences

2. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences

3. Department of Public Health, Nagoya City University Graduate School of Medical Sciences

4. Department of Pharmacy, College of Pharmacy, Kinjo Gakuin University

5. Department of Internal Medicine, Aioiyama Hospital

Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Subject

Pharmacology (medical),Pharmacology

Link

https://www.jstage.jst.go.jp/article/jscpt/43/6/43_375/_pdf

Reference31 articles.

1. 1) Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999; 99(22): 2858-60.

2. 2) McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001; 154(1): 229-36.

3. 3) Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T, et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol. 2004; 43(12): 2219-24.

4. 4) Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis. 2005; 181(2): 321-7.

5. 5) Nakamura T, Obata JE, Takano H, Kawabata K, Sano K, Kobayashi T, et al. High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis. 2009; 202(1): 234-40.